Cargando…

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study

SIMPLE SUMMARY: Treatment of small HER2+ breast cancers with adjuvant Trastuzumab is still controversial. This study aims to measure the effect of Trastuzumab in early stages of breast cancer (pT1mic/a pN0/1mi) in terms of disease recurrence and to identify which factors most affect the prognosis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villasco, Andrea, Actis, Silvia, Bounous, Valentina Elisabetta, Borella, Fulvio, D’Alonzo, Marta, Ponzone, Riccardo, De Sanctis, Corrado, Benedetto, Chiara, Biglia, Nicoletta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616482/ https://www.ncbi.nlm.nih.gov/pubmed/34830989 http://dx.doi.org/10.3390/cancers13225836

Ejemplares similares

Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study
por: Accomasso, Francesca, et al.
Publicado: (2023)

Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy
por: D’Alonzo, Marta, et al.
Publicado: (2019)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Rosso, Roberta, et al.
Publicado: (2023)

Surgery after Neoadjuvant Chemotherapy: A Clip-Based Technique to Improve Surgical Outcomes, a Single-Center Experience
por: Minella, Carola, et al.
Publicado: (2022)

Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients
por: Villasco, Andrea, et al.
Publicado: (2021)

Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
por: Biglia, Nicoletta, et al.
Publicado: (2016)

Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome
por: Modaffari, Paola, et al.
Publicado: (2019)

Prognostic Factors Research in Breast Cancer Patients: New Paths
por: Susini, Tommaso, et al.
Publicado: (2022)

FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact
por: Metovic, Jasna, et al.
Publicado: (2022)

Nipple-sparing mastectomy: external validation of a three-dimensional automated method to predict nipple occult tumour involvement on preoperative breast MRI
por: D’Alonzo, Marta, et al.
Publicado: (2019)

Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
por: Biglia, Nicoletta, et al.
Publicado: (2014)

Pseudoangiomatous Stromal Hyperplasia (PASH) of the Breast: An Uncommon Finding in an Uncommon Patient
por: Surace, Alessandra, et al.
Publicado: (2020)

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
por: Cont, Nicoletta Tomasi, et al.
Publicado: (2015)

Gynecological Cancers in Lynch Syndrome: A Comparison of the Histological Features with Sporadic Cases of the General Population
por: Bounous, Valentina Elisabetta, et al.
Publicado: (2022)

Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update
por: Biglia, Nicoletta, et al.
Publicado: (2019)

Immunohistochemical Markers and TILs Evaluation for Endometrial Carcinoma
por: Bounous, Valentina Elisabetta, et al.
Publicado: (2022)

Low-Grade Uterine Endometrial Stromal Sarcoma: Prognostic Analysis of Clinico-Pathological Characteristics, Surgical Management, and Adjuvant Treatments. Experience From Two Referral Centers
por: Borella, Fulvio, et al.
Publicado: (2022)

Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
por: Tosca, Elena M., et al.
Publicado: (2023)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers
por: Borella, Fulvio, et al.
Publicado: (2022)

Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2015)

Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers
por: Borella, Fulvio, et al.
Publicado: (2022)

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
por: Palle, Juliette, et al.
Publicado: (2017)

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
por: Boero, Silvia, et al.
Publicado: (2016)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Is There Anything Better than Pt for HER?
por: Hansen, Johannes Novak, et al.
Publicado: (2021)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
por: Li, Qian, et al.
Publicado: (2016)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6prs09gacg5msppno3057mk58g